Navigation Links
Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA)
Date:3/8/2011

GREENSBORO, N.C., March 8, 2011 /PRNewswire/ -- Merz Pharmaceuticals today announced the launch of two programs to provide financial assistance to patients for their treatment with Xeomin® (incobotulinumtoxinA). XEOMIN is a botulinum toxin type A free from accessory proteins that is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with cervical dystonia, to decrease the severity of abnormal head position and neck pain in both botulinum toxin-naive and previously treated patients.  XEOMIN is also approved for the treatment of adults with blepharospasm who were previously treated with onabotulinumtoxinA (Botox®).

The XEOMIN Patient Co-payment Program is easy-to-use and offers eligible patients assistance for their actual out-of-pocket costs for therapeutic treatment with XEOMIN. Eligible treatment-related costs may include the cost of XEOMIN, associated guidance therapy and related administration fees.

Merz also announced the launch of the XEOMIN Patient Assistance Program, a program to provide XEOMIN at no cost to eligible patients who are experiencing financial hardship and who do not have third party drug coverage.

Enrollment in the XEOMIN Patient Co-payment Program or the XEOMIN Patient Assistance Program is simple. Patients who want to learn more about the programs and secure an application form can do so by calling 1-888-4-XEOMIN (1-888-493-6646) or by speaking with their healthcare provider. Dedicated support representatives are available from 8 a.m. until 8 p.m. (EST), Monday through Friday.

"By offering a continuum of XEOMIN financial assistance programs, our hope is to help patients manage their cervical dystonia and blepharospasm costs by reducing or eliminating financial obstacles that may prevent initiation or continuation of treatment," said Jack Britts, President and CEO of Merz Pharmaceuticals, LLC. "At Merz, we understand how difficult it can be to live with chronic cond
'/>"/>

SOURCE Merz Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... ENGLEWOOD, Colo. , Sept. 22, 2014 ... one of the U.S. commercial launch of its foot ... distributed by Paragon 28.  The GORILLA TM R3CON ... 28, joining the Monster TM & Mini-Monster TM ... Systems. Comprised of 10 interchangeable subsystems, the ...
(Date:9/22/2014)... , September 22, 2014 ... has announced the addition of the  "Global ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... to wirelessly operate electronic gadgets such as ... consoles from a short line-of-sight distance. Remote ...
(Date:9/22/2014)... 22, 2014 Final shortlist ...   The second edition of the much-awaited VCCircle ... to announce the final nominations for the 2014 honours. ... the evening of September 25 at The Taj Mahal Palace, ... based on a variety of qualitative and quantitative parameters ...
Breaking Medicine Technology:Paragon 28, Inc. Launches the GORILLA(TM) R3CON PLATING SYSTEM 2Global Remotes Market 2014-2018 2Global Remotes Market 2014-2018 3Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3
... The Pharmaceutical Care Management Association (PCMA) issued the ... hearing: "The independent drugstore lobby continues ... for themselves in Medicaid while demanding more transparency for ... and retail pharmacy allies in the embarrassing role of ...
... Oxford Finance Corporation (Oxford), a subsidiary of ... Debbie Baker to its Business Development group. As director, ... for life science and medical device companies, primarily in ... 30 years of financial experience, predominantly with the healthcare ...
Cached Medicine Technology:PCMA: Independent Drugstore Lobby Continues 'Disclosure Double Standard' Transparency Campaign 2Oxford Finance Corporation Hires Debbie Baker to Support Life Science Business Development in Western North America 2
(Date:9/22/2014)... Rockville Centre, NY (PRWEB) September 22, 2014 ... Goodwin, before whom all of the federal mesh ... Boston Scientific Corp. have been consolidated for pretrial ... re: Boston Scientific Corp. Pelvic Repair System Products ... Southern District of West Virginia; Case no. 2:12-md-02326)—requiring ...
(Date:9/22/2014)... News) -- Teens and young adults at risk for ... help prevent risky sexual behaviors, according to new recommendations ... year, about 20 million new sexually transmitted infections such ... About half involve people between 15 and 24 years ... new report, published Sept. 22 in Annals of ...
(Date:9/22/2014)... September 22, 2014 Manhattan residents who ... side of the hip , which could be bursitis ... This treatment is now offered at New York Dynamic ... called trochanteric bursitis, occurs when the trochanteric bursa becomes ... in the hip, between the iliotibial band and the ...
(Date:9/22/2014)... to 40 percent of patients undergoing breast cancer surgery ... all the cancerous tissue in the initial operation. However, ... tested a tool they developed that will help surgeons ... decreasing the chances for repeat operations. ... September 22, 2014 in the Proceedings of the ...
(Date:9/22/2014)... Hamilton, ON (September 22, 2014) South Asians living ... and double the rate of diabetes compared with while ... was published today in the Canadian Medical Association ... http://www.cmajopen.ca/content/2/3/E183.full , One of the fastest-growing ethnic ... million South Asian people living in Canada, comprising about ...
Breaking Medicine News(10 mins):Health News:Federal Court Sets Trial Date for Boston Scientific Vaginal Mesh Cases in Florida, the Rottenstein Law Group LLP Reports 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 3Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 2Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 3Health News:The fine line between breast cancer and normal tissues 2Health News:Higher risk of heart disease for South Asians in Canada 2
... 19 /PRNewswire-FirstCall/ - Notification of Year End,2007 Earnings Webcast ... (TSX: RBM) Year End 2007 Earnings Webcast and ... To listen to this Webcast and Conference Call ... To participate in the live conference call please dial ...
... Using the Canadian Light Source synchrotron, an international team led ... detailed structure of the enzyme the Norwalk virus uses to ... itself. The information is crucial to developing drugs that could ... viruses. , The Norwalk virus uses the enzyme, RNA ...
... (OTC,Bulletin Board: RXEI), a developer, manufacturer, and marketer of ... its,2007 year-end financial results in a conference call on ... Company will release its 2007 year-end financial results after ... call will be,RxElite CEO Jonathan Houssian, COO Earl E. ...
... ST. LOUIS, March 18 Sigma-Aldrich (Nasdaq:,SIAL) announced ... its $300 million,revolving credit facility established in December ... feature. Under the revised $450 million,revolving credit facility, ... and,$420 million will mature on December 11, 2012. ...
... The Pharmaceutical Care,Management Association (PCMA) issued the ... that are being,debated in Congress:, "PCMA ... drug,therapies is an important tool in promoting ... way with Pharmacy & Therapeutics,(P&T) committees and ...
... mental acuity may actually improve , , TUESDAY, March 18 ... treatment, head-and-neck cancer patients experience decreases in their physical ... quality of life, says a U.S. study. , ... that head and neck cancer treatment such as feeding ...
Cached Medicine News:Health News:Scientists see Norwalk virus' Achilles heel 2Health News:RxElite Inc. Fourth Quarter and Year-End 2007 Earnings Release and Conference Call Notice 2Health News:Head and Neck Cancer Outcomes a Mixed Bag 2
... The new Amsco 3080/3085 SP Bariatric ... width capacity and expanded surgical capabilities for ... extensions are rated for patients up to ... and easy attachment and full positioning capability. ...
... The new Amsco 3080/3085 SP Bariatric Foot ... capacity and expanded surgical capabilities for Amsco ... The Amsco Foot Extension is rated for ... designed for secure and easy attachment and ...
... The Pulsavac Plus System offers a ... Debridement System. High power efficiently clears bone ... Specific tips are available for hip and ... a wide range of pressure options for ...
The Simpulse Solo Pulsed Lavage System requires minimal set up and has a Wide range of tips available for every orthopaedic procedure. It uses a separate suction lumen to reduce clogging and n ergono...
Medicine Products: